Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer
Autor: | S. E. Namkoong, Ahwon Lee, Jong-Sup Park, Yong Gyu Park, Jeong-Hoon Bae, Seog-Nyeon Bae, Sung Jong Lee |
---|---|
Rok vydání: | 2008 |
Předmět: |
Oncology
Adult medicine.medical_specialty medicine.medical_treatment Uterine Cervical Neoplasms Hysterectomy Disease-Free Survival Young Adult Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radical Hysterectomy Radical surgery Neoadjuvant therapy Etoposide Aged Neoplasm Staging Cervical cancer Chemotherapy business.industry Obstetrics and Gynecology Middle Aged medicine.disease Neoadjuvant Therapy Regimen Chemotherapy Adjuvant Female Cisplatin business medicine.drug Follow-Up Studies |
Zdroj: | Gynecologic oncology. 111(3) |
ISSN: | 1095-6859 |
Popis: | Objectives We aimed to determine the efficacy and feasibility of neoadjuvant chemotherapy (NACT) using cisplatin and etoposide in patients with locally advanced cervical cancer. Methods Previously untreated patients with histologically confirmed stage 1B–2B cervical cancer were treated with three courses of NACT (60 mg/m2 cisplatin on days 1 and 2 plus 100 mg/m2 etoposide on day 1) every 10 days. NACT was followed within 2–3 weeks by radical hysterectomy with lymph node dissection. Results From 1999 to 2004, 112 patients were enrolled and 99 patients were evaluable. All eligible patients had radical surgery after NACT. Hematologic toxicity was the most common side effect, and the level of toxicity was acceptable. The overall pathologic response rate was 69.7% (69/99). The median follow-up period was 49 months, and the 5-year overall and progression-free survival rates were 88.1% and 60.5%, respectively. Conclusion NACT with cisplatin and etoposide for patients with locally advanced cervical cancer is promising and has an acceptable toxicity profile. The regimen timing (every 10 days) did not delay the optimal time for radical treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |